

Professor Gregory R. Grant



Happy Halloween

<u>Teaching Assistants</u> Chetan Vadali Jianing Yang

Introduction to ioinformatics **Bioinformatics Topic 13 Pathway Enrichment Analysis** October 31st, 2023 **Gregory R. Grant Genetics Department** ggrant@pennmedicine.upenn.edu

ITMAT Bioinformatics Laboratory University of Pennsylvania



What comes after *q*-values?

- What is done after *q*-values have been computed in an RNA-Seq DE analysis?
 - Case 1: All *q*-values equal 1, or are close to it, then we cannot reasonably conclude any genes are DE.
 - In spite of how low some *p*-values might seem.
 - Case 2: Only a few *q*-values are small, like 10 or 20, and all other *q*-values are 1 or close to it.
 - Case 3: Many genes, like hundreds or thousands of *q*-values are small, so hundreds or thousands of genes are DE.

Case 1

- No genes appear DE
 - Do not conclude no genes are DE.
 - We just failed to reject the null hypothesis.
 - Could simply be a matter of power.
- Were there enough replicates?
- Could power be increased by revisiting normalization, searching for batch effects, running a different DE statistical test (or app)?





ullet

 \bullet

Case 3

- There are hundreds or thousands of DE genes.
 - This is very often the case.
 - It's not practical to investigate them individually.
 - Might drill down on some interesting looking ones.
 - It can take months if not years to investigate one gene.
 - This won't get you very far down a list of hundreds unless you get lucky and chase exactly the right gene.
 - Instead, when there are hundreds, they typically fall into categories.
 - It's not typically genes that are DE between conditions, it's pathways.

Categories of Genes

- A category is a set of genes with some meaningful relation.
- There are many types of categories.
 - They can be functional (*e.g.,* clock genes), structural (*e.g.,* ribosomal genes), involved in the same processes (*e.g.,* cell cycle genes), etc.
 - Each category has multiple genes, and each gene will belong to multiple categories.
 - Genes/Categories is a many-to-many relationship.
- There are several working groups that have undertaken the task of categorizing genes.
- GO for example.

GENEDATOROCO	Abeat Calology	Annelations Develoads	Нар	0	* f shaver
	01	Gurrent	1.603.740 pere p	3,525 GQ terms 7 reducts 6,257 spi	.ens.384 annetation
THE G	ENE ONT	OLOGY F	RESOUR	CE	
The masion of the	50 Consolium is is develop		tational model of	O Enrichment /	Analysis 🛛
species in the two of	es, ranging from the molecus lite.	ar to the organism level, ao	oss the multiplicity of	four gene IDs here	
The Gene Detalogy of genes. This know	OOI knewledgebase is the wi ledge is both human-readebl	old's largest source of inform to and machine-mastable, an	dies a feature for		
research			18	biological process	v
Search GO term of	Gene Product in AmiGO		٩	r oan ane binthai 12AC, Ona 2015a	Anne Cove Symbols
Any Ontology	Gene Product		-V	- 10 A.	





Current release 2022-10-07: 43,329 GO terms | 7,694,564 annotations 1,503,740 gene products | 5,257 species (see statistics)

THE GENE ONTOLOGY RESOURCE

The mission of the GO Consortium is to develop a comprehensive, **computational model of biological systems**, ranging from the molecular to the organism level, across the multiplicity of species in the tree of life.

The Gene Ontology (GO) knowledgebase is the world's largest source of information on the functions of genes. This knowledge is both human-readable and machine-readable, and is a foundation for computational analysis of large-scale molecular biology and genetics experiments in biomedical research.

Search GO term or Gene Product in AmiGO ...

Any Ontology Gene Product

GO Enrichment Analysis ?

Powered by PANTHER

Q

biological process	2	Ň
Homo capion y	Examples	Launch 🕽





KEGG PATHWAY Database

Wiring diagrams of molecular interactions, reactions and relations

KEGG2	PATHWAY	BRITE	MODULE	ко	GENES	COMPOUND	NETWOR	RK DISEASE	DRUG
Select I map	orefix Organisn	n Enter	keywords				Go	Help	
Dulla								[New path	way maps Update history]

Pathway Maps

KEGG PATHWAY is a collection of manually drawn pathway maps representing our knowledge of the molecular interaction, reaction and relation networks for:



Enrichment

- Suppose a set of genes comes from a DE analysis between two experimental conditions C₁ and C₂.
 - Or from wherever, really.
- The set is "enriched" in a particular gene category if there are more genes from that category than we'd expect by chance.
 - Suppose for example that only 1% of *all* genes are involved in the cell cycle.
 - But 80% of the DE list are cell cycle genes.
 - That (strongly) indicates the difference between C₁ and C₂ has something to do with the cell cycle.
 - $\circ~$ Perhaps cells in C_1 are actively dividing and those in C_2 are quiescent.







Terminology

People refer to this as "Pathway Enrichment Analysis"

- Even if they are interested in all types of categories, not jut "pathways".
- It's also commonly called a "GO Analysis"
 - Even though "GO" is a particular collection of gene sets from 'The Gene Ontology Resource'.

Also "Gene Set Enrichment Analysis"

Even though GSEA is a particular algorithm, it's also used generically.

Types Of Algorithms



Algorithms

- There are many algorithms that take a list of genes and determine which (if any) categories of genes are overrepresented on the list.
- This is generally known as "Pathway Analysis"

The Hypergeometric Test

- By far the most common and most straightforward approach is to model the problem by the hypergeometric distribution.
- As usual, this method makes a simplifying assumption.
 - For example, it assumes gene expression is independent between genes, which is definitely not true.



The Hypergeometric Random Variable

- Start with a set of *N* things.
- Randomly choose one subset of m things and another subset of n things.
- The observed value of the random variable is the size of the intersection, *y*.
- Note: If you look up (or google) the hypergeometric, you'll find it defined in a different (but equivalent) way.
 - We are using this formulation because it's the best one for modeling pathway enrichment analysis.



y is random

- *N, m* and *n* are fixed.
- Each time we choose two subsets of sizes *m* and n, the size of their overlap *y* will vary.
- The probability distribution of y is called the "hypergeometric distribution".
 - We'll look at some graphs in a few slides.
 - It doesn't look much different from a normal, except with finite tails.



The Hypergeometric Distribution

- The hypergeometric distribution depends on three parameters.
 - Three positive integers.
 - *N*, *n* and *m*.
 - You have a set *S* of *N* things.
 - You select *n* of them at random.
 - Put them in a set S₁
 - You select *m* of them at random.
 - Put them in a set S₂
 - Let *Y* be the size of $S_1 \cap S_2$
- If we choose the sets S_1 and S_1 at random from the set of N things, then Y is a random variable.



p-values

• The distribution function of the hypergeometric random variable gives us P(Y = y) where y is an observed value of the random variable.

$$P(Y = y) = \frac{\binom{N}{y}\binom{N-m}{n-y}}{\binom{N}{y}}$$

- The *p*-value is (as usual) the probability of an observed value or more extreme.
- For an observed intersection of size *k* the *p*-value is:

$$\sum_{i=k}^{\min\{m,n\}} P(Y=i)$$

The Hypergeometric Distribution - Three Examples -



Intuition

- Here the intersection is about what you'd expect.
 - Overlap not significant.
 - Large hypergeometric *p*-value
- Here the intersection is higher than you'd expect.
 - Overlap significant
 - Small hypergeometric *p*-value.





Relation to Enrichment Analysis



- A separate test is performed for each pathway.
- The resultant *p*-values are then multiple-testing corrected to *q*-values, usually by Benjamini-Hochberg.

Example Results Table

• The input was a set of DE genes in an RNA-Seq experiment

Category :	Term	¢ RT	Genes	Count	<u>%</u> 👙	P-Value	Benjamini 🖨
GOTERM_CC_DIRECT	cytosol	RT		64	32.5	3.8E-6	1.1E-3
GOTERM_CC_DIRECT	nucleus	RT	-	82	41.6	7.3E-5	1.1E-2
GOTERM_MF_DIRECT	aminoacyl-tRNA ligase activity	<u>RT</u>		5	2.5	4.6E-4	8.7E-2
GOTERM_MF_DIRECT	protein kinase binding	<u>RT</u>	=	15	7.6	4.8E-4	8.7E-2
GOTERM_BP_DIRECT	translation	RT		11	5.6	6.2E-4	7.2E-1
GOTERM_CC_DIRECT	cytosolic ribosome	<u>RT</u>	—	6	3.0	7.1E-4	7.0E-2
GOTERM_CC_DIRECT	<u>cytoskeleton</u>	<u>RT</u>		25	12.7	9.6E-4	7.0E-2
GOTERM_MF_DIRECT	protein binding	<u>RT</u>		67	34.0	9.7E-4	1.2E-1
GOTERM_BP_DIRECT	tRNA aminoacylation for protein translation	<u>RT</u>		4	2.0	3.6E-3	1.0E0
GOTERM_MF_DIRECT	hydrolase activity, acting on glycosyl bonds	<u>RT</u>	—	5	2.5	5.0E-3	4.1E-1
GOTERM_CC_DIRECT	nucleoplasm	RT		45	22.8	5.4E-3	2.3E-1
GOTERM_MF_DIRECT	aminoacyl-tRNA editing activity	<u>RT</u>	-	3	1.5	5.6E-3	4.1E-1
GOTERM_BP_DIRECT	metabolic process	RT	—	7	3.6	6.3E-3	1.0E0
GOTERM_CC_DIRECT	<u>Golgi apparatus</u>	<u>RT</u>	-	23	11.7	6.6E-3	2.3E-1
GOTERM_CC_DIRECT	histone deacetylase complex	<u>RT</u>	—	4	2.0	6.6E-3	2.3E-1
GOTERM_CC_DIRECT	ribosome	<u>RT</u>	=	7	3.6	7.4E-3	2.3E-1
GOTERM_CC_DIRECT	membrane	RT		76	38.6	7.4E-3	2.3E-1
GOTERM_CC_DIRECT	polysome	RT		4	2.0	8.0E-3	2.3E-1
GOTERM_BP_DIRECT	cytoplasmic translation	<u>RT</u>		5	2.5	8.2E-3	1.0E0
GOTERM_CC_DIRECT	cytosolic small ribosomal subunit	<u>RT</u>	-	4	2.0	8.9E-3	2.4E-1
GOTERM_CC_DIRECT	microtubule organizing center	<u>RT</u>		6	3.0	9.7E-3	2.4E-1
GOTERM_BP_DIRECT	regulation of translation	<u>RT</u>	—	6	3.0	1.1E-2	1.0E0
GOTERM_BP_DIRECT	cellular response to epidermal growth factor stimulus	<u>RT</u>		4	2.0	1.2E-2	1.0E0
GOTERM_CC_DIRECT	trans-Golgi network	<u>RT</u>	=	7	3.6	1.3E-2	2.8E-1
GOTERM_BP_DIRECT	carbohydrate metabolic process	<u>RT</u>		7	3.6	1.3E-2	1.0E0
GOTERM_CC_DIRECT	cell projection	RT	-	19	9.6	1.4E-2	3.0E-1
GOTERM_CC_DIRECT	endoplasmic reticulum	RT		24	12.2	1.5E-2	3.0E-1
UP_KW_DOMAIN	Zinc-finger	RT		23	11.7	1.7E-2	3.0E-1
GOTERM_MF_DIRECT	RNA binding	RT		16	8.1	1.7E-2	8.3E-1
GOTERM_MF_DIRECT	valine-tRNA ligase activity	<u>RT</u>	a -	2	1.0	1.8E-2	8.3E-1

Enrichment Analysis Free Servers

- There are several online resources for pathway enrichment analysis.
 - All of which seem to be based on the hypergeometric test.
- DAVID



- U.S. Government
- https://david.ncifcrf.gov/gene2gene.jsp

ENRICHR

- Mount Sinai
- https://maayanlab.cloud/Enrichr/
- STRING
 - Has basically every species
 - EMBL, Europe (EMBL, Swiss, Denmark)
 - https://string-db.org/cgi/input?input page active form=multiple identifiers









ENRICHR

The interface is simple enough, just paste in your gene identifiers.



Speaking of Identifiers

- It specifically asks for Entrez gene symbols.
 - But the list might come to you as ENSEMBL ID's, RefSeq ID's, UCSC ID's, GENCODE ID's, etc.
 - So, you might have to do some ID conversion first.
- ENRICHR only works for mouse and human.
- DAVID is more flexible, but also pickier and buggier.

 This is the DE results from some old human fibroblast microarray data.

E -bash	\times
Upregulated Genes	
ID Fold-Change q-val	
spp1 1.8729 0.015 cxcr4 1.3826 0.015 rimp1 1.5253 0.015 Runx1 1.4677 0.015 Clec4n 1.762 0.02 Mmp3 1.3509 0.022 pclk1 1.3832 0.027 Top2a 1.5814 0.027 S8104177H381k 1.6237 0.028 serpina3n 1.3107 0.028 Serpina3n 1.3107 0.028 Mmp12 1.7122 0.028 cacs5 1.616 0.028 P4ha3 1.5362 0.028 Cenpe 1.5139 0.028 Cess 1.4676 0.028 Cks2 1.4676 0.028 Kif11 1.5585 0.028 Kif11 1.5585 0.028 Cks2 1.5071 0.028 Cch32 1.3341 0.028 Cyclath 1.5977 0.028 Cch32 1.3341 0.028 Scl2a1b 1.6797 0.029 Ncapg2 <td></td>	

Paste in the top 100 genes and hit Submit



- From this page there are several categories of gene sets available.
- Select Pathways.



- They have included a large number of pathway. KEGG is a fairly popular one.
 - Kyoto Encyclopedia of Genes and Genomes



- This shows the basic KEGG summary.
- Click on Table.



- "Adjusted *p*-value" here means "*q*-value".
- There's one highly significant and a bunch of others with *q*-value in the 0.1 range.
- There are also several pages of less significant pathways.

KEGG	2021 Human Bar Gra	ph Table Clu	ıstergram	Appyter	© 0
Hover eac	ch row to see the overlapping genes.				
10	\sim entries per page		Search:		
Index	Name	P-value	Adjusted p-value	Odds Ratio	Combined score
1	ECM-receptor interaction	0.00005635	0.006142	13.57	132.77
2	p53 signaling pathway	0.004786	0.1043	9.45	50.46
3	Focal adhesion	0.002480	0.1043	5.71	34.28
4	Regulation of actin cytoskeleton	0.003513	0.1043	5.25	29.69
5	Human papillomavirus infection	0.004483	0.1043	4.16	22.47
6	Complement and coagulation cascades	0.007302	0.1326	8.06	39.65
7	Viral protein interaction with cytokine and cytokine receptor	0.01137	0.1622	6.81	30.47
8	Pathways in cancer	0.01190	0.1622	3.01	13.34
9	Human immunodeficiency virus 1 infection	0.01722	0.2086	4.26	17.29
10	Pyrimidine metabolism	0.02800	0.2628	8.08	28.89
Showing Terms ma	1 to 10 of 109 entries Export entries to table arked with an * have an overlap of less than 5			Prev	vious Next

• Click on Apptyer to get nicer visuals.



KEGG 2021 Human	
CM-receptor interaction *5.64e-05	
ocal adhesion 2.48e-03	
Regulation of actin cytoskeleton 3.51e-03	
luman papillomavirus infection 4.48e-03	
53 signaling pathway 4.79e-03	
Complement and coagulation cascades 7.30e-03	
/iral protein interaction with cytokine and cytokine receptor 1.14e-02	
Pathways in cancer 1.19e-02	
luman immunodeficiency virus 1 infection 1.72e-02	
PI3K-Akt signaling pathway 2.48e-02	
i ż ż ś 4 —log10(p-value)	

Background

- The bigger the background, the less likely subsets are to intersect.
- Therefore, if the background contains genes we didn't bother to measure, then the *p*-values will be artificially smaller than they should be.
- This is particularly a problem when working with microarray data.
 - In RNA-Seq we tend to measure all (or most) genes.
 - But there are reasons it can still be limited.
 - For example, we depend on one set of annotations for quantification that may not have all genes in the default background.
- ENRICHR does *not* let you set your own background.
 - DAVID does and so does Ingenuity.



Ingenuity Pathway Analysis (IPA)

Ingenuity is a private effort

• Spun off of Stanford actually.

They charge a lot of money for their product.

- Their justification is that they claim to have a large team of scientists updating their gene sets constantly.
- They claim to have the most up-to-date and curated gene sets.
- It might be true.



Arbitrary Choices

- We have to make an arbitrary choice of how many genes to include in the analysis.
 - We may only have exactly 200 significant genes with *q*-value < 1.
 - But typically, there are thousands of genes and many possible choices of *q*-value cutoff.
- When running Ingenuity, it can take an hour to get results back.
- So, people will typically try just one or a few cutoffs.

MPV

- Users have long desired a way to avoid this arbitrary choice.
 - It doesn't sound scientific to have to make such judgment calls.
- It would be nice to have a slider-bar you can move that updates the pathway analysis in real time as you move it.
 - But that's a huge amount of "on-the-fly" computation.
- But computation has caught up.
 - Here's a beta version we're working on in my lab.
 - DEMO MPV if there's time.



Hypergeometric Limitations

The hypergeometric test models the problem on independent draws of colored balls from an urn.

In this model, balls in the urn behave independently from each other.

But genes do not operate independently.

There can be two genes that are regulated together, so that they're both always at the same level.

In this case if one is DE then the other must also be DE.

Hypergeometric Assumptions

If we model two dependent genes as two independent balls in an urn, then we've acted like one thing is really two.

Whatever one does, the other must do.

But we're going to calculate *p*-values as if the same thing happened twice by chance when both either happen together or not, so it's really just one thing.

That will make things seem less likely than they really are, making *p*-values smaller than they should be, making us draw false conclusions.



Interpretation

- That's why (just like with BLAST) you should never get excited about a (hypergeometric) *p*-value or *q*-value on the order of 0.05 or even 0.01.
 - Even if there wasn't also a multiple testing issue.
- Therefore, we tend to disregard enrichment *q*-values unless they're particularly small.
 - Like 0.00001 or better yet something like 10E-127

GSEA

- GSEA is the name of an app that tries a different approach.
- Up to now we've been working with a subset of genes determined by a *q*-values cutoff.
- Instead GSEA works with all genes.
- First gene expression is correlated with the class label.
 - Class labels indicate experimental condition.
 - Example on next slide will help clarify what this means.



Expression/Class Correlation

- This shows two genes and their correlation to the class labels, represented as a vector of 0's and 1's.
- There's no pathway in this story yet, that comes later.



GSEA Algorithm

- Next all genes are sorted by their correlations to the class labels.
- Then for each pathway, the genes in the pathway are indicated with dark lines.



- If the pathway has nothing to do with the differential expression between the conditions:
 - Then the dark lines should be randomly distributed uniformly across the x-axis.
- If the dark lines bunch up at either end (or even in the middle)
 - that indicates this gene set has something do with the difference between the conditions.

The GSEA Random Walk

- A random walk is then performed from left to right, going up at every gene in the pathway and down at every gene not in the pathway.
- Steps up are bigger than steps down.
 - This is from the GSEA paper

Calculate enrichment. We set the constant step size of the walk, so that it begins and ends with 0, and the area under the running sum is fixed to account for variations in gene set size. We walk down the list *L*, incrementing the running sum statistic by

 $\sqrt{(N-N_h)/N_h}$ when we encounter a gene in S and decrementing by $\sqrt{N_h/(N-N_h)}$ if the gene is not in S, where N is the number of genes in the list L, and N_h is the number of genes in the gene set S. The maximum deviation from zero is the ES for the gene set S, and corresponds to a standard Kolmogorov-Smirnov statistic.

The GSEA Enrichment Score

- The score for that gene set is then the maximum height achieved by the random walk.
 - Though a completely different problem, they were obviously inspired by BLAST
- Here the walk is represented by the green line.



GSEA Report

- A *p*-value is then calculated, which are then multiple-testing corrected for there being multiple gene sets.
- They use a non-parametric (permutation) approach to *p*-values, which is an upcoming topic.



6.874 CELL ADHESION MOLECULES -6.047 PROTEIN PROCESSING IN ENDOPLASMIC RETICULUM 6.039 ECM-RECEPTOR INTERACTION 5.300 CALCIUM SIGNALING PATHWAY 5.297 STAPHYLOCOCCUS AUREUS INFECTION 5.189 PROTEIN DIGESTION AND ABSORPTION -5.086 SPINOCEREBELLAR ATAXIA 4.876 COMPLEMENT AND COAGULATION CASCADES 4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	NES	SET
6.047 PROTEIN PROCESSING IN ENDOPLASMIC RETICULUM 6.039 ECM-RECEPTOR INTERACTION 5.300 CALCIUM SIGNALING PATHWAY 5.297 STAPHYLOCOCCUS AUREUS INFECTION 5.189 PROTEIN DIGESTION AND ABSORPTION 5.086 SPINOCEREBELLAR ATAXIA 4.876 COMPLEMENT AND COAGULATION CASCADES 4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	6.874	CELL ADHESION MOLECULES
6.039 ECM-RECEPTOR INTERACTION 5.300 CALCIUM SIGNALING PATHWAY 5.297 STAPHYLOCOCCUS AUREUS INFECTION 5.189 PROTEIN DIGESTION AND ABSORPTION -5.086 SPINOCEREBELLAR ATAXIA 4.876 COMPLEMENT AND COAGULATION CASCADES 4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	-6.047	PROTEIN PROCESSING IN ENDOPLASMIC RETICULUM
5.300 CALCIUM SIGNALING PATHWAY 5.297 STAPHYLOCOCCUS AUREUS INFECTION 5.189 PROTEIN DIGESTION AND ABSORPTION -5.086 SPINOCEREBELLAR ATAXIA 4.876 COMPLEMENT AND COAGULATION CASCADES 4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	6.039	ECM-RECEPTOR INTERACTION
5.297 STAPHYLOCOCCUS AUREUS INFECTION 5.189 PROTEIN DIGESTION AND ABSORPTION -5.086 SPINOCEREBELLAR ATAXIA 4.876 COMPLEMENT AND COAGULATION CASCADES 4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	5.300	CALCIUM SIGNALING PATHWAY
5.189 PROTEIN DIGESTION AND ABSORPTION -5.086 SPINOCEREBELLAR ATAXIA 4.876 COMPLEMENT AND COAGULATION CASCADES 4.876 COMPLEMENT AND COAGULATION CASCADES 4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	5.297	STAPHYLOCOCCUS AUREUS INFECTION
-5.086 SPINOCEREBELLAR ATAXIA 4.876 COMPLEMENT AND COAGULATION CASCADES 4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	5.189	PROTEIN DIGESTION AND ABSORPTION
4.876 COMPLEMENT AND COAGULATION CASCADES 4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	-5.086	SPINOCEREBELLAR ATAXIA
4.787 RIBOSOME BIOGENESIS IN EUKARYOTES 4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	4.876	COMPLEMENT AND COAGULATION CASCADES
4.690 UBIQUITIN MEDIATED PROTEOLYSIS 4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	-4.787	RIBOSOME BIOGENESIS IN EUKARYOTES
4.674 AMYOTROPHIC LATERAL SCLEROSIS 4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	-4.690	UBIQUITIN MEDIATED PROTEOLYSIS
4.647 PROTEASOME 4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	-4.674	AMYOTROPHIC LATERAL SCLEROSIS
4.619 SYSTEMIC LUPUS ERYTHEMATOSUS 4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	-4.647	PROTEASOME
4.584 NEUROACTIVE LIGAND-RECEPTOR INTERACTION 4.512 FOCAL ADHESION	4.619	SYSTEMIC LUPUS ERYTHEMATOSUS
4.512 FOCAL ADHESION	4.584	NEUROACTIVE LIGAND-RECEPTOR INTERACTION
	4.512	FOCAL ADHESION

